Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Chemotherapy. The Angeles Clinic and Research Institute, Santa Monica, CA, United States



Survival: 11.0 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Santa Monica, CA
   
Hospital: The Angeles Clinic and Research Institute
   
Journal: Link
   
Date: 7/2011

Description:
Patients:
This phase II study involved stage IV melanoma patients who were divided into three separate treatment groups. Group A consisted of 32 patients with a median age of 64 years; 56% were male. Group B consisted of 32 patients with a median age of 60 years; 56% were male. Group C consisted of 33 patients with a median age of 61 years; 79% were male.

Treatment:
Patients in group A were treated with the chemotherapy agent dacarbazine.

Patients in group B were treated with dacarbazine and the biologic therapy agent intetumumab, which is an anti-integrin monoclonal antibody that interferes with getting blood to the tumor.

Patients in group C were treated with the biologic therapy agent intetumumab alone.

Toxicities:
The most severe adverse reactions in group A were grade 4 neutropenia, thrombocytopenia, and shortness of breath.

The most severe adverse reactions in group B were grade 4 anemia, leukopenia, and neutropenia. Grade 3 headache was also reported.

The most severe adverse reactions in group C were grade 3 fatigue, headache, and abdominal pain

Results:
The median overall survival rates for groups A, B, and C were 8, 11, and 15 months, respectively.

Support:
This study was supported by Centocor Ortho Biotech, makers of intetumumab.

Correspondence: Dr. S. O’Day ; email: soday@theangelesclinic.org

E-mail to a Friend Email Physician More Information